PURIXAN Drug Patent Profile
✉ Email this page to a colleague
When do Purixan patents expire, and what generic alternatives are available?
Purixan is a drug marketed by Nova Labs Ltd and is included in one NDA.
The generic ingredient in PURIXAN is mercaptopurine. There are ten drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the mercaptopurine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Purixan
A generic version of PURIXAN was approved as mercaptopurine by DR REDDYS LABS SA on February 11th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PURIXAN?
- What are the global sales for PURIXAN?
- What is Average Wholesale Price for PURIXAN?
Summary for PURIXAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 310 |
| Clinical Trials: | 2 |
| Patent Applications: | 2,135 |
| Drug Prices: | Drug price information for PURIXAN |
| What excipients (inactive ingredients) are in PURIXAN? | PURIXAN excipients list |
| DailyMed Link: | PURIXAN at DailyMed |
Recent Clinical Trials for PURIXAN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cancer Institute (NCI) | Phase 3 |
| Millennium Pharmaceuticals, Inc. | Phase 1 |
| Massachusetts General Hospital | Phase 1 |
Pharmacology for PURIXAN
| Drug Class | Nucleoside Metabolic Inhibitor |
| Mechanism of Action | Nucleic Acid Synthesis Inhibitors |
US Patents and Regulatory Information for PURIXAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nova Labs Ltd | PURIXAN | mercaptopurine | SUSPENSION;ORAL | 205919-001 | Apr 28, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for PURIXAN
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Nova Laboratories Ireland Limited | Xaluprine (previously Mercaptopurine Nova Laboratories) | mercaptopurine | EMEA/H/C/002022 Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children. |
Authorised | no | no | no | 2012-03-09 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
